Search for: "Matter of Roche"
Results 361 - 380
of 415
Sorted by Relevance
|
Sort by Date
29 Jun 2023, 12:29 am
T 0438/19 of 27-06-2023 referred the following questions to the Enlarged Board of Appeal for decision:1. [read post]
9 May 2007, 1:34 pm
The Reporters take the position that aggregating litigation is simply a matter of degree, and we disagree. [read post]
7 Apr 2023, 10:51 am
Opening Keynote by Irene Roche-Laguna of the European Commission’s DGCONNECT group on origins and aspirations for the DSA People thought it couldn’t be done; didn’t know whether it would be a directive or a regulation. [read post]
20 Jan 2022, 6:01 am
All 21 of the defendants belong to the corporate families AstraZeneca, GE Healthcare, Johnson & Johnson, Pfizer or Roche. [read post]
24 Apr 2020, 6:58 am
(The federal government did not do so.)Irrespective of the merits of 1498 as a general matter, in the context of a crisis such as the COVID-19 pandemic we see real value in bold, “nuclear option” use of section 1498 to save billions on high-priced prescription drugs and maximize their availability. [read post]
16 Nov 2009, 4:47 pm
Roche, 08-55286. [read post]
10 Jan 2009, 3:20 pm
There was also the minor matter of talent, or rather me coming f2f with its absence. [read post]
11 Oct 2015, 4:55 pm
In addition, at the roughly same time, Vice Chancellor John Noble withheld his approval of a shareholder settlement in a merger objection lawsuit arising from Roche’s $8.3 million acquisition of InterMune. [read post]
25 Nov 2009, 3:00 am
(BLOG@IP::JUR) (PatLit) Transmission of information in Europe – patentable subject matter? [read post]
11 Mar 2019, 10:15 am
Roche, 546 U.S. 81, 84 (2005) [read post]
25 Oct 2010, 9:15 am
WilliamsDocket: 09-1380Issue(s): Whether, when federal subject matter jurisdiction is not in question, and thus principles of ordinary, rather than complete, preemption are applicable, defenses that require analysis of a collective-bargaining agreement may substantively preempt state-law claims under Section 301 of the Labor Management Relations Act, or whether such defenses are categorically irrelevant to preemption analysis.Certiorari-Stage Documents:Opinion below (8th Circuit)Petition… [read post]
27 Oct 2011, 4:24 am
The Accutane plaintiffs allege that Roche failed to warn about side effects like inflammatory bowel disease and birth defects. [read post]
27 Apr 2007, 12:04 pm
Issa suggested that perhaps "one window" might be provided for a post-grant proceeding, one shot at a patent, no matter when that window would be. [read post]
12 Jun 2011, 4:13 am
While some cases are challenging for the Court because the area of the law is difficult or complex, others deal with a subject matter that is equally difficult to understand. [read post]
17 Jan 2021, 6:15 pm
Of course, before the court will make a finding of publication, the plaintiff must also satisfy the requirements of the second component of publication on a balance of probabilities, namely, that the “defamatory matter [was] brought by the defendant or his agent to the knowledge and understanding of some person other than the plaintiff” (McNichol, at p. 704). [read post]
7 Sep 2012, 3:23 pm
That there had been various recalls of similar models didn’t matter since none of them had involved the device in question or the risk in question. [read post]
26 May 2011, 7:09 am
Hoffmann-La Roche, Inc. v. [read post]
12 Dec 2014, 5:06 am
My post on Wednesday morning has attracted a large number of comments, including many thoughtful contributions, and so I would like to follow up concerning the wider issue of product-by-process claims (independent of the specific Hospira v Genentech case), gathering up, and responding to, some of the comments.In the meantime, readers interested in the decision itself may care to visit the report by Katfriend Suleman Ali (Holly IP) posted on the PatLit blog here, which has a more detailed analysis of… [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram) – Lundbeck wins… [read post]
7 Mar 2008, 2:00 am
: (IPBiz), US: Proposals for the approval of generic biologics under consideration: (Pharmacapsules@Gowlings), US: A paradigm shift in obviousness for pharma, biotech: (IP Law360), US: USPTO’s Bruce Kisliuk addresses ACI Pharma/biotech patent claim drafting and prosecution conference: (Patent Docs), US: New bill to provide biotech companies Sarbanes-Oxley relief: (California Biotech Law Blog), US: Biotech and pharma companies spent millions on lobbying in 2007: (Patent… [read post]
